[Therapeutic efficacy of macrolide anti-infective agents and other pharmacological actions].
Azuma
Arata
A
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy; D017963:Azithromycin / Q000494:pharmacology / Q000627:therapeutic use; D001988:Bronchiolitis / Q000188:drug therapy; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000188:drug therapy; D004917:Erythromycin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015964:Gene Expression Regulation, Bacterial / Q000187:drug effects; D006801:Humans; D018942:Macrolides / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D009077:Mucins / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000201:enzymology; D010196:Pancreatic Elastase / Q000378:metabolism; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000235:genetics; D029424:Pulmonary Disease, Chronic Obstructive / Q000517:prevention & control; D020545:Respiratory Mucosa / Q000378:metabolism; D012852:Sinusitis / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000890:Anti-Infective Agents; D018942:Macrolides; D009077:Mucins; D004917:Erythromycin; D017963:Azithromycin; D010196:Pancreatic Elastase